Jianjun Zhang
M.D. Anderson Cancer Center · RenJi Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jianjun Zhang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:57 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07038915 · STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1M.D. Anderson Cancer Center · withdrawn · Lung Squamous Cell Carcinoma, Anti-PD1/PDL1 Antibody · principal investigator
- Ph4NCT06353126 · DEB-TACE Prior to Liver Transplantation in the Treatment of HCCRenJi Hospital · recruiting · Liver Cancer · principal investigator
- N/ANCT06069037 · SALT for Treatment of Patients With Early ACLFRenJi Hospital · unknown · Acute-On-Chronic Liver Failure · principal investigator
- Ph2NCT04789681 · Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung TrialM.D. Anderson Cancer Center · recruiting · Lung Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8 · principal investigator
- Ph2NCT03634241 · Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung StudyM.D. Anderson Cancer Center · completed · Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic responseU01CA256780 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2021 to 2025 · $605,520 awarded in 2025Same name and institution; not confirmed by an ID
- The molecular and immune evolution in the progression of lung neoplasia to invasive adenocarcinomaR01CA234629 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2023 · $358,680 awarded in 2023Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:57 UTC. The ranking covers the 200 most relevant of 128 PubMed records, and a shared surname and initials can bring in a namesake. All 128 on PubMed
- Pembrolizumab for the treatment of non-small-cell lung cancer.N Engl J Med · 20155,273 citationsRCR 161.1
- 2,888 citationsRCR 106.9
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.N Engl J Med · 20181,689 citationsRCR 52.2
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.Cancer Discov · 20181,464 citationsRCR 44.3
- 1,090 citationsRCR 44.6
- 936 citationsRCR 31.8
- Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.N Engl J Med · 2022912 citationsRCR 57.5
- 567 citationsRCR 26.2
- 392 citationsRCR 42.0
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.J Clin Oncol · 2018376 citationsRCR 11.1